NextGen inks alliance with Paragon Bioservices

NextGen Sciences, a wholly owned subsidiary of NextGen Group and provider of gene-to-protein products and services, has formed a commercial alliance with Paragon Bioservices in Baltimore, a provider of contract research and manufacturing services in support of developing biologics.

The alliance expands the portfolio of both companies with the ability to offer an integrated offering including molecular biology, protein production, proteomics, functional assay development, biomarker discovery and monitoring, the Cambridgeshire, U.K.-based NextGen said.

NextGen said the alliance extends its commitment to expand their fee for service offering in strategic partnerships in addition to adding new capabilities in house such as the protein biomarker monitoring services, announced in November 2007.

Paragon Bioservices of Baltimore and NextGen have agreed to co-market each others fee-for-service offerings to the market that allows client companies to choose a one-stop shop for their entire gene to protein needs, according to both companies.

Around the web

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.